Openpay (ASX:OPY) share price tumbles 6% on increasing loss

The Openpay (ASX:OPY) share price is slumping 6% today after the company released its half-year results for FY21. Here's the lowdown.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Openpay Group Ltd (ASX: OPY) shares are tumbling today after the company released its half-year results for FY21. At the time of writing, the Openpay share price is slumping 6.23% to $2.71.

Let's take a look at how the buy now, pay later (BNPL) provider has been performing.

A man wearing glasses and a checkered shirt looks gobsmacked as he puts his hand to his cheek, representing the fall of the Zip share price is cheek

Image source: Getty Images

What's impacting the Openpay share price?

The Openpay share price is taking a dive on Friday as the Afterpay Ltd (ASX: APT) competitor posted a loss of $25.7 million. This represents an increase of around 37% on the $16.1 million loss posted in the prior corresponding period (pcp). While Openpay's revenues were up $5.4 million on the pcp, its expenses increased by $15 million.

The large increase in outgoings was driven by a $6.4 million change in the fair value of derivatives, a $4 million lift in employee-related expenses, a $2.8 million increase in receivables impairment expenses, and a $1.3 million increase in marketing and advertising expenses.

In a silver lining for the Openpay share price, the company's earnings per share (EPS) loss was down from 0.37 cents in the pcp to 0.24 cents.

No dividends were declared for the half-year ended 31 December 2020.

Words from the CEO

Striking an optimistic tone, Openpay CEO Michael Eidel said:

H1 was a scene setter for Openpay. We announced a highly targeted and customised strategy to enter the US – one of the world's biggest payments markets, leveraging deep industry experience and knowledge. Having built a strong Retail customer base in the UK, we are now preparing to bridge into Healthcare and Automotive – two verticals which have driven Openpay's differentiation in Australia. Through our B2B product, OpyPro, we are positioned to tap into the multi-trillion-dollar enterprise payments market.

Current and future endeavours

As highlighted by the CEO, Openpay is attempting to differentiate itself from its competitors by focusing on the B2B sector. Having already signed a deal with Woolworths Group Ltd (ASX: WOW) for its OpyPro system (formerly Openpay for Business), the company is looking to further expand, particularly in the United Kingdom market.

Openpay has 1.4 million active plans (a 213% jump on the pcp) and approximately 2,700 active merchants (up 46% on the pcp).

Possible headwinds

While in its announcement, Openpay highlighted the fact it has "a strong mix of available cash and debt for a total funding runway of $173 million", the auditor's report was less upbeat.

In its review report, Price Waterhouse Coopers (PWC) gave the following note on the "material uncertainty related to the going concern":

The Group incurred a net operating cash outflow of $37.2 million and a net loss of $25.5 million for the half-year ended 31 December 2020. The ability of the Group to continue as a going concern is dependent upon maintaining existing cash reserves and debt facilities and securing additional debt facilities and/or the issue of new shares.

PWC added:

These conditions…indicate that a material uncertainty exists that may cast significant doubt on the Group's ability to continue as a going concern.

Openpay share price snapshot

Over the past year, the Openpay share price has surged by more than 135%. However, looking at the last six months, Openpay shares have plunged by nearly 40%.

Based on the current Openpay share price, the company has a market capitalisation of around $250 million.

The Motley Fool Australia owns shares of AFTERPAY T FPO and Woolworths Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy hump day session for the ASX.

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

Scientists working in the laboratory and examining results.
Opinions

3 reasons to buy CSL shares today

The ASX biotech company has great growth potential this year.

Read more »

a man weraing a suit sits nervously at his laptop computer biting into his clenched hand with nerves, and perhaps fear.
Share Fallers

Why Brightstar, EQ Resources, Novonix, and Pro Medicus shares are falling today

These shares are under pressure on hump day. But why?

Read more »

A happy family of four on holidays stand on a jetty and cheer.
Broker Notes

Down 40% in 2026, should you buy the big dip in Life360 shares?

A leading analyst offers his outlook for Life360 shares.

Read more »

Buy and sell on yellow paper with pins on them and several share price lines.
Broker Notes

Sell alert! Why this expert is calling time on Nuix and Brainchip shares

A leading analyst forecasts more pain to come for Brainchip and Nuix shares. But why?

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Share Gainers

Why EOS, Humm, New Hope, and Sims shares are storming higher today

These shares are having a good session on hump day. But why?

Read more »

a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming
Broker Notes

With global populations ageing, are ResMed shares a good buy today?

A leading expert delivers his verdict on the outlook for ResMed shares.

Read more »